Drug search by name

Etoposide Oral, Intravenous and Myelosuppression

Result of checking the interaction of drug Etoposide Oral, Intravenous and disease Myelosuppression for safety when used together.

Check result:

Etoposide Oral, Intravenous <> Myelosuppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Etoposide induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3. Clinical monitoring of hematopoetic function is recommended. Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy. At least one determination should be done prior to each dose.

References:

DeVore R, Higa G, Robbins A, Sarkar M "Protracted infusion of low-dose etoposide (E): preliminary results of a Phase I/II pharmacokinetic (PK) study (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a4491993
Lokich J Corkery J "Phase I study of VP-16-213 (Etoposide) administered as a continuous 5- day infusion." Cancer Treat Rep 65 (1981): 887-9
Niederle N Ostermann J Achterrath W Lenaz L Schmidt CG "Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study." Cancer Chemother Pharmacol 28 (1991): 59-62
Kobayashi K, Ratain MJ "Pharmacodynamics and long-term toxicity of etoposide." Cancer Chemother Pharmacol 34 Suppl (1994): s64-8
"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.

Etoposide Oral, Intravenous

Generic Name: etoposide

Brand Name: VePesid, Etopophos, Toposar

Synonyms: Etoposide

What is Etoposide Oral, Intravenous?